Schedule 13D ownership disclosure

ATARA BIOTHERAPEUTICS INC

Common Stock · CUSIP: 046513107

Event date: 2025-08-15

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Panacea Innovation LimitedReported CIK 0002010692

    Shares: 1,712,900 · Class: 20.0%

  • Panacea Venture Healthcare Fund II, L.P.Reported CIK 0001869939

    Shares: 1,405,000 · Class: 20.0%

  • Panacea Venture Healthcare Fund II GP Company, Ltd.

    Shares: 1,405,000 · Class: 20.0%

  • Panacea Opportunity Fund I, L.P.Reported CIK 0001869966

    Shares: 307,900 · Class: 4.2%

  • Panacea Opportunity Fund I GP Company, Ltd.

    Shares: 307,900 · Class: 4.2%

  • James HuangReported CIK 0001573160

    Shares: 1,712,900 · Class: 20.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-110311
Form type
SCHEDULE 13D/A
Filer
Atara Biotherapeutics, Inc.
CIK
CIK 1604464
Filed
Aug 19, 2025
Reporting period
Aug 15, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub